Neurological Biomarkers Market Analysis, Revenue Share, Company Profiles, Launches, & Forecast Till 2025
Posted by sneha j on August 4th, 2022
The neurological biomarkers market for Alzheimers disease generated a revenue of ,636.7 million in 2017, and is expected to reach ,122.5 million by 2025, registering a CAGR of 11.1% from 2018 to 2025. Conversely, neurological biomarkers market for Parkinsons disease generated a revenue of ,321.8 million in 2017, and is expected to reach ,457.4 million by 2025 registering a CAGR of 8.0%.
Get Detail Report https://www.alliedmarketresearch.com/neurological-biomarkers-market
Upsurge in the incidence of Alzheimers and Parkinsons diseases is anticipated to contribute to the robust growth of neurological biomarkers. In addition, increase in adoption of neurological biomarkers in drug development and validation has been witnessed over the years to improve the accuracy of clinical trials. Furthermore, rise in preference towards personalized medicine is expected to offer profitable opportunities for the expansion of neurological biomarkers applied across Alzheimers and Parkinsons.
Based on the region, the neurological biomarkers market for Alzheimers and Parkinsons diseases is studied across the U.S., EU5, rest of Europe, China, Asia-Pacific, and rest of the world (ROW). The U.S. dominated the market for Alzheimers and Parkinsons in 2017, and is expected to continue this trend throughout the forecast period. In addition, Asia-Pacific is anticipated to grow at the fastest pace in Alzheimers neurological biomarkers market during the forecast period, whereas China is expected to register highest growth rate from 2018 to 2025 in the Parkinsons neurological biomarkers market.
Like it? Share it!
About the Authorsneha j
Joined: July 12th, 2022
Articles Posted: 62
More by this author